Recifercept

瑞夫明西普

Report date: 2023/05/19 20:00:21

Base Information

Drug NameRecifercept
Drug Alias NameTA-46PF-07256472
ClassificationBiologics
Mechanisms of ActionFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 3
Therapy Area/IndicationsAchondroplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPortugal +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesWyeth BioPharma Division of Wyeth Pharmaceuticals LlcPfizer Investment Co Ltd
Active IndicationsN/A
Inactive IndicationsAchondroplasia

Other Information

ATC CodeN/A
Related LinksN/A